0000950170-23-058627.txt : 20231103 0000950170-23-058627.hdr.sgml : 20231103 20231103120110 ACCESSION NUMBER: 0000950170-23-058627 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20231101 ITEM INFORMATION: Entry into a Material Definitive Agreement FILED AS OF DATE: 20231103 DATE AS OF CHANGE: 20231103 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Clearside Biomedical, Inc. CENTRAL INDEX KEY: 0001539029 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 452437375 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37783 FILM NUMBER: 231375133 BUSINESS ADDRESS: STREET 1: 900 NORTH POINT PARKWAY STREET 2: SUITE 200 CITY: ALPHARETTA STATE: GA ZIP: 30005 BUSINESS PHONE: 678-270-3631 MAIL ADDRESS: STREET 1: 900 NORTH POINT PARKWAY STREET 2: SUITE 200 CITY: ALPHARETTA STATE: GA ZIP: 30005 8-K 1 clsd-20231101.htm 8-K 8-K
0001539029false00015390292023-11-012023-11-01

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 01, 2023

 

 

Clearside Biomedical, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-37783

45-2437375

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

900 North Point Parkway

Suite 200

 

Alpharetta, Georgia

 

30005

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 678 270-3631

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.001 per share

 

CLSD

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 1.01 Entry into a Material Definitive Agreement.

On November 1, 2023, Clearside Biomedical, Inc. (the “Company”) entered into a license agreement (the “License Agreement”) with BioCryst Pharmaceuticals, Inc. (“BioCryst”) pursuant to which the Company granted BioCryst an exclusive, worldwide and sublicensable license to the Company’s SCS Microinjector for the delivery of BioCryst’s proprietary plasma kallikrein inhibitor known as avoralstat for the treatment and prevention of diabetic macular edema (“DME”).

The Company will receive an upfront license fee of $5.0 million in connection with signing of the License Agreement. In addition, the Company is eligible to receive up to an additional $30.0 million in clinical and regulatory milestone payments, and up to a total of $47.5 million in a series of post-approval sales-based milestone payments based on the achievement of annual global net product sales milestones up to $2.0 billion. Further, during the royalty term, BioCryst has also agreed to pay the Company tiered mid-single digit royalties on annual global net product sales, with the highest royalty rate applied to sales over $1.5 billion, subject to reductions in specified circumstances.

BioCryst will be responsible for all development, regulatory and commercialization activities for avoralstat. The Company is responsible for supplying SCS Microinjectors to meet BioCryst’s reasonable needs.

During the term of the License Agreement, the Company has agreed not to (i) develop or commercialize, whether on its own or through partnership with a third party, any kallikrein inhibitor delivered via the Company’s SCS Microinjector for use in ocular disease and (ii) grant any license of the patent rights licensed to the Company by Emory University and Georgia Tech Research Corporation (together with Emory University, the “Licensors”) pursuant to the License Agreement, by and among the Company and the Licensors, dated July 4, 2012, as amended, to any third party to develop or commercialize any kallikrein inhibitor delivered via the Company’s SCS Microinjector for use in ocular disease. In addition, during the term of the License Agreement, BioCryst has agreed not to, whether on its own or through partnership with a third party, develop or commercialize a product incorporating (i) avoralstat for use in ocular disease or (ii) another kallikrein inhibitor for the treatment of DME, in each case that is administered or delivered through the use of a device for delivery of therapeutic agents to the eye other than the SCS Microinjector.

The License Agreement, unless earlier terminated, will expire (a) on a country-by-country basis upon the expiration of the royalty term in such country or (b) in its entirety upon the expiration of all payment obligations of BioCryst under the License Agreement in all countries pursuant to clause (a). Each party has the right terminate the License Agreement (i) upon a material breach of the License Agreement by the other party, subject to a specified cure period and specified exceptions, or (ii) if the other party encounters bankruptcy or insolvency. The Company may terminate the License Agreement if BioCryst or any of its sublicensees (a “Sublicensee”) commences a legal action challenging the validity, enforceability or scope of any of the licensed patents, provided that with respect to any such action initiated by a Sublicensee (a “Sublicensee Action”), the Company may terminate the License Agreement if the Sublicensee Action is not terminated within a specified period of time following BioCryst’s receipt of written notice from the Company or if BioCryst does not terminate the applicable sublicense, in each case within a specified period of time. BioCryst may terminate the License Agreement (i) immediately upon written notice to the Company if, after exercising commercially reasonable efforts, BioCryst determines in good faith that it is not advisable to continue development or commercialization of avoralstat as a result of a material safety issue and (ii) in its entirety or in part on a country-by-country basis, for any or no reason, upon prior written notice to the Company, provided that in the event of such a termination, BioCryst shall not, for a period of two years from the date of such a termination, initiate in the territory subject to the termination a Phase 3 clinical trial in which avoralstat is administered to the suprachoroidal space using a device other than the SCS Microinjector.

The foregoing is a summary description of certain terms of the License Agreement, is not complete and is qualified in its entirety by reference to the text of the License Agreement, which the Company expects to file as an exhibit to the Company’s Annual Report on Form 10-K for the year ending December 31, 2023.

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 3, 2023

CLEARSIDE BIOMEDICAL, INC.

By:

/s/ Charles A. Deignan

Name:

Charles A. Deignan

Title:

Chief Financial Officer

 

 EX-101.PRE 2 clsd-20231101_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.SCH 3 clsd-20231101.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 clsd-20231101_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Securities Act File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications XML 5 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Document And Entity Information
Nov. 01, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 01, 2023
Entity Registrant Name Clearside Biomedical, Inc.
Entity Central Index Key 0001539029
Entity Emerging Growth Company false
Securities Act File Number 001-37783
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 45-2437375
Entity Address, Address Line One 900 North Point Parkway
Entity Address, Address Line Two Suite 200
Entity Address, City or Town Alpharetta
Entity Address, State or Province GA
Entity Address, Postal Zip Code 30005
City Area Code 678
Local Phone Number 270-3631
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol CLSD
Security Exchange Name NASDAQ
XML 6 clsd-20231101_htm.xml IDEA: XBRL DOCUMENT 0001539029 2023-11-01 2023-11-01 0001539029 false 8-K 2023-11-01 Clearside Biomedical, Inc. DE 001-37783 45-2437375 900 North Point Parkway Suite 200 Alpharetta GA 30005 678 270-3631 false false false false Common Stock, par value $0.001 per share CLSD NASDAQ false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://clearsidebio.com/20231101/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports clsd-20231101.htm clsd-20231101.xsd clsd-20231101_lab.xml clsd-20231101_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "clsd-20231101.htm": { "nsprefix": "clsd", "nsuri": "http://clearsidebio.com/20231101", "dts": { "inline": { "local": [ "clsd-20231101.htm" ] }, "schema": { "local": [ "clsd-20231101.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "clsd-20231101_lab.xml" ] }, "presentationLink": { "local": [ "clsd-20231101_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://clearsidebio.com/20231101/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_d9ba6913-e7cd-482c-99fd-b2c33f5755d2", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "clsd-20231101.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_d9ba6913-e7cd-482c-99fd-b2c33f5755d2", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "clsd-20231101.htm", "first": true, "unique": true } } }, "tag": { "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://clearsidebio.com/20231101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://clearsidebio.com/20231101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://clearsidebio.com/20231101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://clearsidebio.com/20231101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://clearsidebio.com/20231101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://clearsidebio.com/20231101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://clearsidebio.com/20231101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://clearsidebio.com/20231101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://clearsidebio.com/20231101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://clearsidebio.com/20231101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://clearsidebio.com/20231101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://clearsidebio.com/20231101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://clearsidebio.com/20231101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://clearsidebio.com/20231101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://clearsidebio.com/20231101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://clearsidebio.com/20231101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://clearsidebio.com/20231101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://clearsidebio.com/20231101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Securities Act File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://clearsidebio.com/20231101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://clearsidebio.com/20231101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://clearsidebio.com/20231101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://clearsidebio.com/20231101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://clearsidebio.com/20231101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 13 0000950170-23-058627-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-058627-xbrl.zip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